Home / ASCO Direct Highlights / ASCO Direct Highlights - South Carolina / Continuing Education Credits - South Carolina

Continuing Education Credits - South Carolina

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported in part by educational grants from Astellas and Seattle Genetics, Celgene Corporation, Exelixis, Inc., Pfizer, Inc., and TESARO, Inc.

Target Audience

Multidisciplinary clinical cancer care team members including—but not limited to—medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

Overview

Overview: ASCO DIRECT™ HIGHLIGHTS MEETINGS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting, into a one-day program. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty will place abstract findings into clinical context and discuss how the results may change the current standard of care.

Objectives:

At the end of this educational activity, participants should be able to:

  • Review highlights of the advances in clinical and translational research presented at the 2019 ASCO Annual Meeting
  • Identify emerging trends and strategies designed to improve the quality of survivorship care
  • Evaluate tools and resources in specific areas of cancer management that can be used to achieve effective cancer care delivery and improve the patient experience

Agenda

6:30 – 7:30 AM   Registration and Networking Breakfast

7:30 – 7:40 AM   Introduction and Pre-Activity Assessment

7:40 – 8:10 AM   Breast Cancer VK Gadi, MD, PhD

8:10 – 8:40 AM    Healthcare Delivery and Survivorship Jennie R. Crews, MD, MMM, FACP

8:40 – 9:40 AM    Hepatobiliary/Pancreatic/Gastrointestinal Cancers Aaron J Scott MD

9:40 – 10:05 AM  Networking Break

10:05 – 10:35 AM  Melanoma and Skin Cancers Ragini Kudchadkar, MD

10:35 – 11:05 AM  Gynecologic Cancers Bradley J. Monk, MD, FACS, FACOG

11:05 – 11:40 AM   Genitourinary Cancers Oliver Sartor, MD

11:40 AM – 12:25 PM  Networking Lunch

12:25 – 12:55 PM  Leukemia/Lymphoma Suzanne R. Fanning, DO

12:55 – 1:25 PM  Multiple Myeloma Jonathan L. Kaufman, MD

1:25 – 1:55 PM  CAR T-cell Therapies Krishna Komanduri, MD

1:55 – 2:25 PM  Quality Management and Care Improvement Jennie R. Crews, MD, MMM, FACP

2:25 – 2:45 PM  Networking Break

2:45 – 3:15 PM   Cancer Genomics and Molecular Diagnostics Jeffrey Gregg, MD

3:15 – 3:45 PM  Lung Cancer Taofeek K. Owonikoko, MD, PhD                      

3:45 – 4:00 PM  Program Evaluation/Q&A

Faculty

  • Breast Cancer, VK Gadi, MD, PhD, University of Washington; Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance
  • Healthcare Delivery and Survivorship, Jennie R. Crews, MD, MMM, FACP, SCCA Community Sites; SCCA Affiliate Network 
  • Hepatobiliary/Pancreatic/Gastrointestinal Cancers, Aaron J. Scott MD, Oncology Clinical Consensus Group; University of Arizona Cancer Center
  • Melanoma and Skin Cancers, Ragini Kudchadkar, MD, Emory University School of Medicine
  • Gynecologic Cancers, Bradley J. Monk, MD, FACS, FACOG, University of Arizona College of Medicine; Creighton University School of Medicine at St. Joseph's Hospital Phoenix
  • Genitourinary Cancers, Oliver Sartor, MD, Tulane Cancer Center; Tulane Medical School
  • Leukemia/Lymphoma, Suzanne R. Fanning, DO, University of South Carolina School of Medicine – Greenville
  • Multiple Myeloma, Jonathan L. Kaufman, MD, Winship Cancer Institute, Emory University School of Medicine
  • CAR T-cell TherapiesKrishna Komanduri, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System
  • Quality Management and Care Improvement, Jennie R. Crews, MD, MMM, FACP, SCCA Community Sites; SCCA Affiliate Network
  • Cancer Genomics and Molecular Diagnostics, Jeffrey Gregg, MD, University of California, Davis Medical Center; Foundation Medicine, Inc
  • Lung Cancer, Taofeek K. Owonikoko, MD, PhD, Emory University

 

Continuing Education

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

IPCE LogoThis activity was planned by and for the healthcare team, and learners will receive 7.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Credit Designation for Pharmacists
This application-based activity is approved for 7.0 contact hours of continuing pharmacy education credit JA4008106-9999-19-026-L01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 7.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

 

Name of Faculty or Presenter/Planner

Reported Financial Relationship

VK Gadi, MD, PhD

VK Gadi, MD PhD reported a financial interest/relationship or affiliation in the form of Consultant: Seattle Genetics; Novartis Pharmaceuticals Corp; Puma Biotechnology; Biotheranostics. Research grant: Roche; Signal-One Bio; Agendia. Ownership interest: SEngine Precision Medicine. Intellectual property, royalty: SEngine Precision Medicine; PNP Therapeutics; Chimerocyte, Inc.

Jennie R. Crews, MD, MMM, FACP

Jennie R. Crews, MD, MMM, FACP  reported no financial interest/relationships.

Aaron J. Scott, MD

Aaron J. Scott MD reported no financial interest/relationships.

Ragini Kudchadkar, MD

Ragini Kudchadkar, MD reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co.; Array; Immunocore. Research grant: Merck & Co, Inc.; Regeneron.

Bradley J. Monk, MD, FACS, FACOG

Bradley Monk, MD, FACS, FACOG, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie, Inc.; Advaxis, Inc., Agenus; Amgen;  AstraZeneca Pharmaceuticals LP; ChemoCare; ChemoID; Clovis Oncology; Conjupro Bio-Pharmaceuticals; Easai, Inc.; Geistlich Pharma; Genmab; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; Mateon (Oxigene, Inc.); Merck & Co., Inc., Myriad Genetics, Inc.; NuCana; OncoMed Pharmaceuticals; OncoQuest, Inc.; OncoSec Medical Incorporated; Perthera, Inc.; Pfizer, Inc.; Precision Oncology; Puma Biotechnology; Genentech/Roche; Samumed; Takeda Oncology; Tesaro; VBL Therapeutics.  Serve(d) as a speaker or a member of a speakers bureau for:  AstraZeneca Pharmaceuticals LP; Clovis Oncology; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; Genentech/Roche; Tesaro.

Oliver Sartor, MD

Oliver Sartor, M.D. reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Bayer Pharmaceuticals Corp; Progenic Pharmaceuticals; Endocyte; EMD Serono, Inc; Fusion Pharmaceuticals; AAA Pharmaceutical; Noria; Janssen Oncology; Pfizer, Inc.; Blue Earth Diagnostics.  Research grant: Bayer Pharmaceuticals Corp; Progenic Pharmaceuticals; Endocyte; AAA Pharmaceutical;  Janssen Oncology; Sanofi; Merck & Co, Inc.; Invitae Corporation. Received income in any amount from: AstraZeneca Pharmaceuticals LP; Bayer Pharmaceuticals Corp;  Progenic Pharmaceuticals;  Endocyte;  EMD/Serono Inc.; Fusion Pharmaceuticals; AAA  Pharmaceutical;  Noria;  Janssen Oncology; Pfizer Inc.; Blue Earth Diagnostics. Ownership interest: Lilly, USA.

Suzanne R. Fanning, DO

Suzanne R. Fanning, DO reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: Celgene Corporation; Takeda Oncology./p>

Jonathan L. Kaufman, MD

Jonathan L. Kaufman, MD reported a financial interest/relationship or affiliation in the form of Received income in any amount from: Celgene Corporation; Takeda Oncology; Amgen; Janssen Oncology; Sanofi/Genzyme, Bristol-Myers Squibb Co.

Krishna Komanduri, MD

Krishna Komanduri, MD reported a financial interest/relationship or affiliation in the form of Consultant: Kite Pharma/Gilead Sciences, Inc.; Novartis Pharmaceuticals Corp.; Celgene Corporation; Kiadis Pharma; Atara Biotherapeutics; Helocyte; Autolus Therapeutics. Contracted research: Kite Pharma/Gilead Sciences, Inc.; Atara Biotherapeutics; Autolus Therapeutics; Kiadis Pharma.

Jeffrey Gregg, MD

Jeffrey Gregg, MD reported a financial interest/relationship or affiliation in the form of Consultant: Foundation Medicine, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corp. Research grant: AstraZeneca Pharmaceuticals LP.

Taofeek K. Owonikoko, MD, PhD

Taofeek K. Owonikoko, MD, PhD reported a financial interest/relationship or affiliation in the form of Consultant: Novartis Pharmaceuticals Corp.; Celgene Corporation; Lilly USA; Sandoz; Abbvie, Inc.; Eisai, Inc.; G1 Therapeutics, Inc.; Takeda Oncology; Seattle Genetics; Bristol-Myers Squibb Co.; MedImmune; BerGenBio; Amgen; AstraZeneca Pharmaceuticals LP; PharmaMar; Boehringer Ingelheim; EMD Serono, Inc.; Xcovery; Bayer HeatlhCare, Inc.; Heron Therapeutics; ARMO BioSciences, Inc. Research grant to institution: Novartis Pharmaceuticals Corp.; Astellas Pharma US; Celgene Corporation; Bayer HeatlhCare, Inc.; Stemcentrx; Regeneron; AstraZeneca Pharmaceuticals LP/Medimmune; Abbvie, Inc.; G1 Therapeutics, Inc.; Bristol-Myers Squibb Co.; Corvus Pharmaceuticals; United Therapeutics; Amgen; Loxo Oncology/Lilly USA; Fujifilm; Pfizer, Inc.; Aeglea BioTherapeutics; Incyte Corporation; Merck & Co. Inc. Data and Safety Monitoring Board: EMD Serono, Inc.; Genentech/Roche. Have a 5% or greater interest in: Cambium Medical Technologies. Ownership interest: Cambium Medical Technologies.

 


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Planner/Manager/Reviewer

Reported Financial Relationship

Keola Beale, MD

Nothing to disclose

Chuck Miller, MD

Nothing to disclose

Emily Touloukian, DO

Nothing to disclose

Asutosh “Bobby” Gor, MD

Nothing to disclose

Jennie Crews, MD, MMM, FACP

Nothing to disclose

Ali McBride, PharmD, MS, BCOP

Advisor: Bristol-Myers Squibb

John Allan, MD

Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

Stuart P. Feldman, MD

Nothing to disclose

Gene Saylors, MD

Nothing to disclose

Leigh Boehmer, PharmD, BCOP

Nothing to disclose

Mary Stanley

Nothing to disclose

Robert Mocharnuk, MD

Common stock: Merck

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Dee Morgillo, MEd.,CHCP

Nothing to disclose

 

Disclaimer  

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be emailed to you within 3 weeks. For pharmacists, your record will be uploaded to CPE Monitor.

Co-Hosts

South Carolina    logo-ACCC-200x80

Supporters

This activity is supported in part by educational grants from Astellas and Seattle Genetics, Celgene Corporation, Exelixis, Inc.,  Pfizer, Inc., and TESARO, Inc.